79 results about "Mean fluorescence intensity" patented technology

The invention relates to a set of a kit for detecting specificity platelet antoantibody by the combination of monoclonal antibody and nano-microspheres. The kit comprises each 3 ml of four types of monoclonal antibody-polystyrene nano-microspheres PBS solution, 6 ml goat-anti-human polyclonal antibody and PBS solution, wherein the four types of the monoclonal antibody-polystyrene nano-microspheres PBS solution are sealed by bovine serum albumin and are respectively connected with a monoclonal antibody SZ-2, a monoclonal antibody SZ-22, a monoclonal antibody SZ-21, a monoclonal antibody 7E3, and the concentration of polystyrene nano-microspheres is 2 mg / ml; the goat-anti-human polyclonal antibody is connected with fluorescein isothiocyanate and with the concentration of the goat-anti-human polyclonal antibody is 15 mug / ml. A detection process of the specificity platelet antoantibody comprises the following steps of: oscillating monoclonal antibody--microspheres and platelet lysis buffer sample for incubation; washing by PBS; adding the goat-anti-human polyclonal antibody connected with the fluorescein isothiocyanate; washing, re-suspending by the PBS; detecting on a flow cytometry to obtain average fluorescence intensity values of the four types of the nano-microspheres respectively; and confirming whether the specificity platelet antoantibody is positive or not according to a ratio of the obtained values to a basic contrast value of that of a healthy person, in order to provide foundation for early diagnosis of ITP. The detection has the advantages of simple process, high sensitivity and good specificity.

The invention provides a method for rapidly and nondestructively detecting astaxanthin in C.zofingiensis cells. The method comprises the following steps of (1) re-suspending algal cells collected from a known C.zofingiensis suspension sample to regulate the known C.zofingiensis suspension sample into heavy suspension with cell density of 6*10(5) to 2*10<6>CFU / mL by virtue of de-ionized water or a phosphate buffer solution, detecting the average fluorescence intensity of the heavy suspension in an FL1 channel or an FL2 channel by virtue of a flow cytometer, and performing linear regression on a log value of the content of astaxanthin in the known C.zofingiensis suspension sample and a log value of the corresponding measured average fluorescence intensity in the FL1 or FL2 channel to obtain a standard curve; (2) preparing a sample to be detected: re-suspending algal cells collected from C.zofingiensis suspension to be detected to regulate the C.zofingiensis suspension to be detected into algal cell heavy suspension to be detected with cell density of 6*10(5) to 2*10<6>CFU / mL by virtue of de-ionized water or a phosphate buffer solution; (3) detecting the average fluorescence intensity of the sample to be detected in the FL1 channel or the FL2 channel by virtue of the flow cytometer, and calculating the content of astaxanthin in the sample to be detected according to the standard curve obtained in step (1). The method has the characteristic of high detection efficiency.

The present invention provides, inter alia, isolated monoclonal and polyclonal anti-tumor endothelial marker 8 (TEM8) antibodies or antigen binding fragments thereof that (a) bind to TEM8 membrane antigen in its native form occurring on the surface of a tumor cell; (b) may be internalized by a tumor cell; (c) bind strongly to tumor cells but not or only minimally to cells which lack expression of TEM8; and (d) are characterized in that the mean fluorescence intensity (MFI) of the antibody or an antigen binding fragment thereof against a mammalian cell line expressing TEM8 is at least two times higher than the MFI against the mammalian cell line not expressing TEM8 at antigen saturation. Chimeric antigen receptors (CARs) including an antigen binding fragment of such antibodies, modified antibodies, compositions, pharmaceutical compositions, and kits including the antibodies according to the present invention, and methods of use are also provided.

The present invention pertains to a molecular biology-based method and kit for measuring the specific growth rate (or cell doubling time) of distinct microbial populations. The method and kit can be used to analyze mixed culture samples that have been exposed to chloramphenicol or other protein synthesis inhibitors for defined times. In a preferred embodiment, the method of the invention (also referred to herein as FISH-RiboSyn) is an in situ method that utilizes fluorescence in situ hybridization (FISH) with probes that target: (1) the 5′ or 3′ end of precursor 16S rRNA; or (2) the interior region of both precursor 16S rRNA and mature 16S rRNA. Images can be captured for a defined exposure time and the average fluorescent intensity for individual cells can be determined. The rate of increase of the whole cell fluorescent intensity is used to determine the specific growth rate. The method of the invention can be attractive for rapidly measuring the specific growth rate (or cell doubling time) of distinct microbial populations within a mixed culture in industries such as environmental systems (water and wastewater treatment systems), bioremediation (optimization of conditions for microbial growth), public health (identification of rapidly growing infectious microbes), and homeland security (identification of rapidly growing bioterrorism agents).

The invention relates to a multi-factor cell factor automatic analysis method. The method comprises the following steps of extracting flow cytometry data in an FCS format or LMD format file; removing cell debris from the FSC-Hs of all the cells; dividing the effective cells into a plurality of cell populations, and re-dividing a plurality of cell populations into two cell populations; dividing the two cell populations into a plurality of cell populations with the same number as the detected cell factors; carrying out peak number detection of a nuclear density probability density function curve on the fluorescence intensity of all cell antibodies APC in each cell population; continuously grouping the cell population; combining the cell population with the cell count less than 60 with the cell population with the nearest distance; enabling each cell population to correspond to the detected cell factors; carrying out outlier detection on the fluorescence intensity of the PE antibodies of all cells in each cell population, and removing outliers; and calculating the average fluorescence intensity of the cell population PE antibody of each cell factor. The method can effectively remove noise interference and intensity fluctuation to obtain accurate fluorescence intensity of the cell population.